Kbc Group Nv Alkermes Plc. Transaction History
Kbc Group Nv
- $32.2 Billion
- Q1 2025
A detailed history of Kbc Group Nv transactions in Alkermes Plc. stock. As of the latest transaction made, Kbc Group Nv holds 7,176 shares of ALKS stock, worth $208,749. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,176
Previous 7,176
-0.0%
Holding current value
$208,749
Previous $206,000
15.05%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ALKS
# of Institutions
410Shares Held
177MCall Options Held
229KPut Options Held
436K-
Black Rock Inc. New York, NY29.1MShares$847 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$530 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.8MShares$343 Million0.05% of portfolio
-
State Street Corp Boston, MA8.02MShares$233 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.88MShares$200 Million3.72% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.78B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...